Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Ningzhen Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7002-1745; OpenAlex author ID A5048428061. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers

Papers 9

  1. A deep-learning radiomics-based lymph node metastasis predictive model for pancreatic cancer: a diagnostic study. Co-author DOI 10.1097/js9.0000000000000469↗
  2. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  3. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. Co-author DOI 10.1002/aac2.12056↗
  4. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … Co-author DOI 10.1002/cam4.4698↗
  5. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases. Co-author DOI 10.1002/cam4.4147↗
  6. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1007/s00464-020-07791-2↗
  7. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  8. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. Co-author DOI 10.1186/s12885-021-09056-0↗
  9. Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEE… Co-author DOI 10.3389/fonc.2019.01386↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 9 shared papers, 2019–2023 · strength 1.37
  2. Xiaxing Deng · 8 shared papers, 2019–2023 · strength 1.18
  3. Yu Jiang · 6 shared papers, 2019–2023 · strength 0.88
  4. Kai Qin · 3 shared papers, 2021–2023 · strength 0.50
  5. Jiabin Jin · 3 shared papers, 2021–2023 · strength 0.47
  6. Chenghong Peng · 3 shared papers, 2021–2022 · strength 0.43
  7. Weishen Wang · 3 shared papers, 2019–2023 · strength 0.42
  8. Dongfeng Cheng · 2 shared papers, 2021–2023 · strength 0.30
  9. Yuanchi Weng · 2 shared papers, 2021 · strength 0.29
  10. Hao Chen · 2 shared papers, 2019–2021 · strength 0.25
  11. Haoda Chen · 1 shared paper, 2023 · strength 0.19
  12. Xiaohua Qian · 1 shared paper, 2023 · strength 0.19
  13. Jun Wang · 1 shared paper, 2023 · strength 0.17
  14. Yuchen Ji · 1 shared paper, 2023 · strength 0.17
  15. Yiran Zhou · 1 shared paper, 2023 · strength 0.17
  16. Shulin Zhao · 1 shared paper, 2022 · strength 0.16
  17. Hao Chen · 1 shared paper, 2021 · strength 0.13
  18. Jiancheng Wang · 1 shared paper, 2021 · strength 0.13
  19. Zhen Huo · 1 shared paper, 2021 · strength 0.13
  20. Ziyun Shen · 1 shared paper, 2019 · strength 0.09
  21. Siyi Zou · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.